Leiters Announces Outsourcing Supply Agreement with Resource Optimization & Innovation (ROi)

Leiters to serve as a contracted 503B compounded pharmaceutical supplier to ROi’s membership

DENVER- Leiters, an FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services, announced today that they have been awarded an outsourcing supply agreement for 503B compounded pharmaceuticals. The 3-year agreement went into effect on June 1, 2018.

ROi serves more than 300 hospitals and 2,800 non-acute facilities across the U.S. Through the agreement, ROi’s members will have access to the Leiters portfolio of high quality patient medications.

Leiters was awarded the agreement after passing ROi’s rigorous onsite quality audit of its new Denver, Colorado 503B cGMP facility.

Moving forward, Leiters and ROi will also collaborate on new product development and work together to address market shortages in order to better serve ROi members and the communities they serve.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

“Our mission at Leiters is to deliver better medicine to more people. We are excited to provide high quality products and services to the ROi members and their patients,” said Robin Smith Hoke, Chief Executive Officer of Leiters.